Stephens Consulting, LLC Exelixis, Inc. Transaction History
Stephens Consulting, LLC
- $422 Billion
- Q2 2025
A detailed history of Stephens Consulting, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Stephens Consulting, LLC holds 7 shares of EXEL stock, worth $257. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7Holding current value
$257% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EXEL
# of Institutions
649Shares Held
256MCall Options Held
1.67MPut Options Held
733K-
Black Rock Inc. New York, NY33.5MShares$1.23 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA28.7MShares$1.06 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA22.5MShares$830 Million4.78% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny14.8MShares$546 Million0.88% of portfolio
-
State Street Corp Boston, MA11.8MShares$434 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.9B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...